Results 201 to 210 of about 376,249 (344)

Modeling Supports Combinatorial Effects Between Pharmacological and Non‐Pharmacological Interventions to Prevent Opioid‐Induced Cardiac Arrest

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Few studies have quantified the effects of non‐pharmacological interventions (e.g., rescue breathing) in the setting of community opioid overdose. We extended a previously validated model for opioid antagonists by incorporating the mechanism of rescue breathing, and quantified combinatorial effects between rescue breathing and various formulations of ...
Bradlee Thrasher   +12 more
wiley   +1 more source

Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts

open access: green, 2015
Matthew Read   +10 more
openalex   +2 more sources

Major Adverse Cardiac Events with Ondansetron: A Systematic Review

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Evidence base: 170 randomized trials, 23,421 adults, predominantly single‐dose IV ondansetron, mean follow‐up 20 days. Observed outcomes: Major adverse cardiac events were rare, no ventricular arrhythmias or torsades de pointes observed. Conclusion: Ondansetron was not associated with increased mortality or serious cardiac arrhythmias in adult ...
Michael Cristian Garcia   +11 more
wiley   +1 more source

Optimizing antenatal corticosteroid therapy for improving outcome of premature infants. [PDF]

open access: yes, 2019
A Donaldson   +19 more
core   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu   +8 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy